Invacare Compliance Challenges, Product Delays Impact Q3 Results
This article was originally published in The Gray Sheet
Executive Summary
Talks with FDA are ongoing about compliance with quality system regulations and a proposed consent decree that would shut down certain operations at a wheelchair manufacturing plant in Elyria, Ohio, executives said during the firm’s Oct. 25 earnings call.
You may also be interested in...
Regulatory News In Brief
FDA begins releasing summary review memos for 180-day PMA supplements as part of a transparency pilot. Invacare and FDA agree on consent decree terms. More regulatory news.
CMS In Brief
Medicare advisors to meet on ventricular assist devices. CMS decides on coverage-with-evidence development for platelet-rich plasma wound care gel. More news from the Medicare agency.
Reimbursement In Brief
Latest news from the Medicare agency and other payers.